Nicholas Berry

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · The Lancet · 2022 · 406 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +7

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Ly‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al. · The Lancet · 2021 · 310 citations · Full text

Pharmacy, Community Medicine, Pharmacotherapy +14

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study

Andrew Ip, Donald A. Berry, Eric Hansen et al. · PLoS ONE · 2020 · 144 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher Butler, Ly‐Mee Yu, Jienchi Dorward et al. · The Lancet Respiratory Medicine · 2021 · 84 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacotherapy +9

The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials

Benjamin R. Saville, Donald A. Berry, Nicholas Berry et al. · Clinical Trials · 2022 · 72 citations

Public Health, Biostatistics, Bayesian Biostatistics +11